These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 16472706

  • 41. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E, Herbst RS.
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [Abstract] [Full Text] [Related]

  • 42. Second-line treatment options in advanced non-small cell lung cancer: current status.
    Cullen M.
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S3-8. PubMed ID: 16472703
    [Abstract] [Full Text] [Related]

  • 43. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [Abstract] [Full Text] [Related]

  • 44. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA.
    Oncogene; 2009 Aug 15; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [Abstract] [Full Text] [Related]

  • 45. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA, Johnson BE.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [Abstract] [Full Text] [Related]

  • 46. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J.
    J Natl Compr Canc Netw; 2003 Jan 15; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [Abstract] [Full Text] [Related]

  • 47. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T, Liu G, Tsao MS.
    Oncogene; 2009 Aug 15; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [Abstract] [Full Text] [Related]

  • 48. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA, Lynch TJ.
    Oncologist; 2009 Apr 15; 14(4):399-411. PubMed ID: 19357226
    [Abstract] [Full Text] [Related]

  • 49. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA, Thatcher N.
    Oncologist; 2008 Apr 15; 13 Suppl 1():37-46. PubMed ID: 18263773
    [Abstract] [Full Text] [Related]

  • 50. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR, Dragnev KH.
    Oncologist; 2005 Jan 15; 10(1):22-33. PubMed ID: 15632250
    [Abstract] [Full Text] [Related]

  • 51. [Chemotherapy in lung carcinoma].
    Egger T, Cerny T.
    Ther Umsch; 1994 Apr 15; 51(4):267-71. PubMed ID: 7514814
    [Abstract] [Full Text] [Related]

  • 52. [Second-line chemotherapy in non-small-cell lung cancer].
    Schütte W.
    Rev Pneumol Clin; 2004 Nov 15; 60(5 Pt 3):4S13-4S16. PubMed ID: 15687987
    [No Abstract] [Full Text] [Related]

  • 53. Optimizing therapy in previously treated non-small cell lung cancer.
    Miller VA.
    Semin Oncol; 2006 Feb 15; 33(1 Suppl 1):S25-31. PubMed ID: 16472706
    [Abstract] [Full Text] [Related]

  • 54. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD, Pasche B, Argiris A.
    Crit Rev Oncol Hematol; 2004 Jun 15; 50(3):175-86. PubMed ID: 15182824
    [Abstract] [Full Text] [Related]

  • 55. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P, Gridelli C, Troiani T, Ciardiello F.
    Oncologist; 2006 Mar 15; 11(3):274-84. PubMed ID: 16549812
    [Abstract] [Full Text] [Related]

  • 56. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T, Gridelli C, Ciardiello F.
    Curr Opin Oncol; 2007 Mar 15; 19(2):98-102. PubMed ID: 17272980
    [Abstract] [Full Text] [Related]

  • 57. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E, Herbst RS.
    Semin Oncol; 2006 Feb 15; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [Abstract] [Full Text] [Related]

    Page: [Previous] [New Search]
    of 3.